Placebo effect in patients with irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 3, 2011, Pages 116-118

  Lu, Ching Liang ^a,b,d   Chang, Full Young ^a,c,d  

^a Division of Gastroenterology   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c Georgetown Univ School of Medicine   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Functional brain imaging; Irritable bowel syndrome; Placebo effect

Indexed keywords

ALOSETRON; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DOPAMINE; NALOXONE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANALGESIA; ARTICLE; DOCTOR PATIENT RELATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IRRITABLE COLON; LOWER ABDOMINAL PAIN; META ANALYSIS (TOPIC); NEUROIMAGING; NEUROTRANSMISSION; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VISCERAL PAIN;

EID: 79953101996     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06651.x     Document Type: Article

References (37)

1. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686-95.
2. Kaptchuk T. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull. Hist. Med. 1998; 72: 389-433.
3. Beecher HK. The powerful placebo. JAMA 1955; 159: 1602-6.
4. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994; 271: 1609-14.
5. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002; 159: 122-9.
6. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-6.
7. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2005; 3: 237-47.
8. Sands BE. The placebo pesponse pate in irritable bowel syndrome and inflammatory bowel disease. Dig. Dis. 2009; 27 (Suppl. 1): 68-75.
9. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to themagnitude of placebo analgesia in an experimental paradigm. Pain 1999; 83: 147-56.
10. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specifi c subsystems. J. Neurosci. 1999; 19: 484-94.
11. Vase L, Robinson ME, Verne GN, Price DD. The contribution of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. Pain 2003; 105: 17-25.
12. Voudouris NJ, Peck CL, Coleman G. Conditioned response models of placebo phenomena: further support. Pain 1989; 38: 109-16.
13. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008; 136: 211-8.
14. Colloca L, Benedetti F. How prior experience shapes placebo analgesia. Pain 2006; 124: 126-33.
15. Lu HC, Hsieh JC, Lu CL etal. euronal correlates in the modulation of placebo analgesia in experimentally-induced esophageal pain: a 3T-fMRI study. Pain 2010; 148: 75-83.
16. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005; 114: 3-6.
17. Colloca L, Benedetti F. Placebos and painkillers: is mind as real asmatter? Nat. Rev. Neurosci. 2005; 6: 545-52.
18. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 312: 654-7.
19. Benedetti F. The opposite eff ects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996; 64: 535-43.
20. Levine JD, Gordon NC. Infl uence of the method of drug administration on analgesic response. Nature 1984; 312: 755-6.
21. Grevert P, Albert LH, Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain 1983; 16: 129-43.
22. Fields HL, Levine JD. Placebo analgesia-a role for endorphins. Trends Neurosci. 1984; 7: 271-3.
23. Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995; 346: 1231.
24. Benedetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog. Neurobiol. 1997; 52: 109-25.
25. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch. Gen. Psychiatry. 2008; 65: 220-31.
26. Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ 2006; 332: 280-3.
27. Patel SM, Stason WB, Legedza A etal. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil. 2005; 17: 332-40.
28. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2010; 32: 144-58.
29. Dorn SD, Kaptchuk TJ, Park JB etal. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol. Motil. 2007; 19: 630-7.
30. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann. Intern. Med. 2002; 136: 817-25.
31. Kaptchuk TJ, Kelley JM, Conboy LA etal. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003.
32. Bingel U, Lorenz J, Schoell E etal. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006; 120: 8-15.
33. Wager TD, Rilling JK, Smith EE etal. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303: 1162-7.
34. Lieberman MD, Jarcho JM, Berman S etal. The neural correlates of placebo effects: a disruption account. Neuroimage 2004; 22: 447-55.
35. Price DD, Craggs J, Verne GN etal. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 2007; 127: 63-72.
36. Berman SM, Chang L, Suyenobu B etal. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002; 123: 969-77.
37. Lee HF, Lu CL, Hsieh JC etal. Aberrant neuro-network in processing of visceral placebo analgesia among IBS patients. Gastroenterology 2010; 138 (Suppl. 1): S-117-18. (abstract).